US2017326245A1PendingUtilityA1

Methods and Compositions Related To Annexin 1-Binding Compounds

Assignee: SANFORD-BURNHAM MEDICAL RES INSTITUTEPriority: Dec 23, 2009Filed: Apr 4, 2017Published: Nov 16, 2017
Est. expiryDec 23, 2029(~3.4 yrs left)· nominal 20-yr term from priority
A61P 43/00A61P 35/00A61K 47/64
42
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Compositions and methods related to annexin 1-binding compounds. Also compositions comprising a moiety and a peptide comprising an amino acid sequence that can bind to a carbohydrate receptor on a cell. Isolated nucleic acids comprising a nucleic acid sequence encoding a peptide comprising an amino acid sequence that can bind to a carbohydrate receptor on a cell. Methods comprising administering to a subject a composition comprising a moiety and a peptide comprising an amino acid sequence that can bind to a carbohydrate receptor on a cell. Methods of targeting a tumor cell in a subject comprising administering to the subject a peptide comprising an amino acid sequence that can bind to a carbohydrate receptor on a cell. Methods of targeting a tumor cell in a subject comprising administering to the subject a composition comprising a moiety and a peptide comprising an amino acid sequence that can bind to a carbohydrate receptor on a cell.

Claims

exact text as granted — not AI-modified
1 . An isolated nucleic acid comprising a nucleic acid sequence encoding a peptide and moiety wherein the peptide comprises an amino acid sequence that can bind to a carbohydrate receptor on a cell. 
     
     
         2 . A method comprising administering to a subject a composition comprising a nucleic acid sequence encoding a peptide and moiety wherein the peptide comprises an amino acid sequence that can bind to a carbohydrate receptor on a cell. 
     
     
         3 . The method of  claim 2 , wherein the subject comprises a cell, wherein the cell is a tumor cell. 
     
     
         4 . The method of  claim 2 , wherein the subject is in need of treatment, wherein the administration treats the subject. 
     
     
         5 . The method of  claim 4 , wherein the subject has cancer, wherein the administration treats the cancer of the subject. 
     
     
         6 . A method of targeting a tumor cell in a subject, the method comprising administering to the subject a composition comprising a nucleic acid sequence encoding a peptide and moiety wherein the peptide comprises an amino acid sequence that can bind to a carbohydrate receptor on a cell. 
     
     
         7 . A method comprising administering to the subject a composition comprising a nucleic acid sequence encoding a peptide and moiety wherein the peptide comprises an amino acid sequence that can bind to a carbohydrate receptor on a cell and detecting the composition in the subject. 
     
     
         8 . The method of  claim 7 , wherein detecting the composition thereby detects a tumor in the subject. 
     
     
         9 . The method of  claim 7 , wherein detecting the composition thereby diagnoses cancer in the subject. 
     
     
         10 . The method of  claim 7 , wherein detecting the composition comprises detecting the level, amount, concentration, or a combination of binding of the composition to cancer tissue in the subject, wherein the level, amount, concentration, or a combination of binding of the composition to cancer tissue in the subject indicates the prognosis of the cancer in the subject. 
     
     
         11 . The method of  claim 7 , further comprising repeating the administration and detection at a later time, wherein a change in the level, amount, concentration, or a combination of binding of the composition to cancer tissue in the subject indicates the progress of the endometriosis in the subject. 
     
     
         12 . The method of  claim 7 , further comprising repeating the administration and detection following treatment, wherein a change in the level, amount, concentration, or a combination of binding of the composition to cancer tissue in the subject indicates the progress the treatment of the cancer in the subject.

Join the waitlist — get patent alerts

Track US2017326245A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.